Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

The appointment of Societe Generale's boss Frederic Oudea as non-executive chairman of Sanofi will be proposed at the next shareholders meeting of the French drugs group, Sanofi said on Monday.

Frederic Oudea to become Sanofi's non-executive chairman

Late- b reaking Dupixent ® (dupilumab) d ata at ERS 2022 s how consistent e fficacy and safety profile for u p to t wo y ears in c hildren a ged 6 to 11 y ears with m oderate-to-severe a sthma

Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma

Press Release: Evolution of the Board of Directors

GlaxoSmithKline

Merck

Morgan Stanley

Novavax

Novartis

Pfizer

It started out relatively small, or as small as a recall of one of the first drugs to top $1 billion in annual sales can be. In September 2019, individual companies began recalling popular heartburn medication Zantac.

This Overlooked Danger Could Tank Big Pharma Stocks

The FDA approves Sanofi's (SNY) Xenpozyme for treating non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.

Sanofi (SNY) Gets FDA Nod for Rare Disease Drug Xenpozyme

Xenpozyme TM ( olipudase alfa- rpcp ) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)

Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)

Sanofi's (SNY) BLA filing for efanesoctocog alfa was based on data from the XTEND-1 pivotal phase III study.

Sanofi (SNY) Hemophilia A Drug BLA Gets FDA Priority Tag

FDA grants priority review to e fanesoctocog alfa for people with hemophilia A

Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A

This recommendation may help reduce the risk of the flu and flu-related complications in this high-risk population Fluzone® High-Dose Quadrivalent (Influenza Vaccine) and Flublok® Quadrivalent (Influenza Vaccine) are both proven to help prevent more cases of flu in older adults compared to a standard-dose vaccine as assessed in randomized controlled trials1,2 In real-world evidence, they also demonstrated a reduction in flu-related complications.3,4 BRIDGEWATER, N.J. , Aug. 26, 2022 /PRNewswire/ -- The Centers for Disease Control and Prevention (CDC) has published the updated Advisory Committee on Immunization Practices (ACIP) guidance granting preferential recommendation for specific flu vaccines in people age 65+ in its Morbidity and Mortality Weekly Report (MMWR), a journal highlighting the latest in public health news and communicating recommendations derived from science-based research.5  Sanofi's Fluzone ® High-Dose Quadrivalent (Influenza Vaccine) and Flublok ® Quadrivalent (Influenza Vaccine) were among the flu vaccines preferentially recommended by the CDC ACIP for adults 65+.

Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report

Sanofi's recent stock rout underscores the pressure on the French drug maker to redouble its efforts in the hunt for new medicines.

Analysis-Meagre medicine cabinet leaves Sanofi unloved

Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.

Is Sanofi A Buy, Despite Recent Stumbles?

Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.

Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down

Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.

Sanofi trial failure halts work on breast cancer treatment amcenestrant

Sanofi's run of bad luck continued Wednesday after the company scrapped a failed breast cancer drug, leading Sanofi stock to crumble. The post Sanofi's Run Of Bad Luck Continues As Pharma Giant Tosses Out A Cancer Drug appeared first on Investor's Business Daily.

Sanofi's Run Of Bad Luck Continues As Pharma Giant Tosses Out A Cancer Drug

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will leverage its AtomNet® platform for computational discovery and research of up to five drug targets. The Atomwise approach shifts the mode of drug discovery away from serendipitous discovery and toward search based on structure, making the drug discovery process mo

Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery

Sanofi's finance chief said on Wednesday that a decline in the French company's share price in response to litigation threats and a cancer drug development setback was strongly exaggerated and posed a buying opportunity for savvy investors.

Sanofi CFO says stock price pummelling grossly overdone

Sanofi provides u pdate on amcenestrant clinical development program

Press Release: Sanofi provides update on amcenestrant clinical development program

Haleon PLC

Johnson & Johnson

Concerns over potential liability for a medication purported to cause cancer sliced billions off the value of several manufacturers of the drug in the past week. But were the cuts too deep?

Potential Lawsuits Causing Zantac Manufacturers Heartburn

New York, New York--(Newsfile Corp. - August 12, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Sanofi SA ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sanofi - SNY

Investors are bracing for billions of dollars in losses due to lawsuits filed over the heartburn drug Zantac.

Zantac Lawsuits Tank Pharma Stocks As Haleon, GSK, Sanofi Issue Defense

Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).

PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation

Thousands of lawsuits have been filed against companies including Sanofi, GlaxoSmithKline, Haleon and Pfizer accusing them of failing to properly warn users of the recalled heartburn drugs' health risks.

Drugmaker stocks slammed over Zantac lawsuit concerns

After a UBS analyst's note sparked a two-day plunge in the drug makers, their shares rallied Friday after they said there is no evidence the heartburn drug causes cancer. A J.P. Morgan note also called the selloff overdone.

GSK and Sanofi Push Back on Zantac Worries. Shares Rebounded.

READING, England--(BUSINESS WIRE)--First patient enrolled in large European clinical study to investigate protection against RSV, the leading cause of infant hospitalisation worldwide

NIHR and Sanofi Announce First Patient Enrolled in Large European Clinical Study to Investigate Protection Against RSV, the Leading Cause of Infant Hospitalisation Worldwide

News for Sanofi Stock (SNY)